Oncology Leads Personalized Medicine


Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-06-01-2015
Volume 24
Issue 6

Study finds that almost 75% of cancer drug candidates rely on biomarker data. 


The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug

Number of compounds in R&D that rely on biomarker data.

Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.

- Tufts CSDD 


Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.